Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome

JCO Precis Oncol. 2024 Jan:8:e2300265. doi: 10.1200/PO.23.00265.

Abstract

Repotrectinib in a patient with NTRK fusion-positive pancreatic carcinoma and congenital long QT syndrome.

MeSH terms

  • Humans
  • Long QT Syndrome* / diagnosis
  • Long QT Syndrome* / drug therapy
  • Long QT Syndrome* / genetics
  • Macrocyclic Compounds*
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / genetics
  • Pyrazoles / therapeutic use
  • Receptor, trkA / genetics

Substances

  • Receptor, trkA
  • repotrectinib
  • Pyrazoles
  • Macrocyclic Compounds